Investor Ideas Potcasts, Cannabis News and Stocks on the Move

Delta, Kelowna, BC - February 5, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/020520-StocksToWatch.mp3

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; (TSX-V: SVS) (TSX: FAF) (OTCQX: FFLWF) (CSE: IAN) (CSE: BHNG) (NASDAQ: WTER)

SHARE PODCAST:

Hear Investor ideas cannabis potcast on iTunes

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we look at a few early announcements.

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) and Solarvest BioEnergy Inc. (TSX-V: SVS) announced that, further to their press release of May 7, 2019, the Parties have agreed to amendments to the Collaborative Research and Development Agreement designed to accelerate progress of the research project that Solarvest is carrying out. Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares to Solarvest, which will enable Solarvest to fund the CBD Research Project. In addition, Solarvest has appointed Dr. Edward J. Brennan, Jr., M.D., FACS, currently the President of FSD Pharma's BioSciences Division, to the board of directors of Solarvest.

The CBD Research Project involves Solarvest utilizing its algae expression platform to modify algae for the production of pharmaceutical-grade cannabinoids ("Project Cannabinoids"). The Solarvest project is progressing on track and has made progress towards this objective. Since this is a cost-intensive project, and, to enable Solarvest to accelerate the pace of the research, FSD Pharma has issued an additional 225,371 FSD Shares to Solarvest.

The Parties have also mutually agreed that Solarvest would benefit from the additional oversight of Dr. Brennan, who brings with him over 25 years of experience in leadership roles at major pharmaceutical companies and clinical research organizations and has a proven track record in drug development.

FSD Pharma may realize substantial benefits if the CBD Research Project is successful, as Solarvest is required to grant FSD Pharma an exclusive, worldwide license to develop and commercialize prescription drugs that can treat diseases affecting the central nervous system, and Solarvest will additionally provide FSD Pharma with a royalty fee on the sale or licensing of certain products derived from the Project Cannabinoids.

Fire & Flower Holdings Corp. (TSX: FAF) (OTCQX: FFLWF), today announced that it begins trading on OTCQX under the symbol "FFLWF".

OTCQX is operated by OTC Markets Group Inc. (OTCQX: OTCM) is an operator of financial markets for 10,000 United States and global securities. Through OTCQX, investors can find current financial disclosures and information, including real time quotes, on Fire & Flower.

"Fire & Flower is very pleased to have taken this step to provide greater trading access to investors based in the United States," shared Trevor Fencott, Chief Executive Officer of Fire & Flower. "We have received significant interest from investors in the United States and listing on OTCQX was a necessary step to provide these opportunities for international investors in our Company."

iAnthus Capital Holdings, Inc. (CSE: IAN) (OTCQX: ITHUF), which owns, operates, and partners with best-in-class regulated cannabis operations across the United States, announced that it has received approval to commence operations at its Pleasantville, NJ cultivation campus. MPX New Jersey, an affiliate of iAnthus, is the ninth Alternative Treatment Center (ATC) in the state to receive a cultivation permit. This marks the tenth state in iAnthus' operational footprint.

On February 3, 2020, the New Jersey Department of Health issued MPX New Jersey a permit to cultivate at the Company's Pleasantville cultivation facility. The 33,000-square-foot facility, when fully built, will include an extraction lab and kitchen as well as cultivation. The facility is expandable to 83,000 square feet and the first harvest is expected in the second quarter of 2020.

The Company's first medical dispensary in New Jersey is expected to open in Atlantic City in the first quarter of 2020. The 1,300-square-foot facility, located just off the boardwalk on S. New York Avenue, will open as a Be. retail store and will service Atlantic City's estimated 24 million annual visitors. The Company is slated to open a larger Be. flagship facility in the same location pending adult use legalization. The locations of the Company's additional future dispensary sites in New Jersey have yet to be determined.

"We are thrilled to be entering the New Jersey market, my home-state and our milestone tenth state market," said Beth Stavola, Chief Strategy Officer of iAnthus and CEO of MPX New Jersey. "With this expansion, we will bring to New Jersey not only clean, safe, and high-quality cannabis products, but jobs and increased economic activity in the Pleasantville and Atlantic City areas. We greatly look forward to servicing the medical marijuana community and being part of a path forward toward full adult-legalization."

New Jersey, the most densely populated state in the U.S. with approximately nine million residents, is currently a medical-use cannabis market. In just under two years since Governor Murphy took office, the number of recommending physicians in the New Jersey Medicinal Marijuana Program has doubled, and the number of patients has more than tripled to more than 66,000. Patients continue to enroll at a rate of approximately 500 a week. Jake Honig's Law, enacted in July 2019, put in place meaningful provisions to expand access for medical patients, including the removal of monthly limits for terminally ill patients.

On December 16, 2019, the NJ Senate and Assembly passed a resolution to add legalization of adult use cannabis as a ballot question for the November 2020 election.

Red Ace Organics a leading organic beverage company and wholly-owned subsidiary of Bhang, Inc. (CSE: BHNG) (OTCQX: BHNGF), announced that a partnership with professional U.S. swimmers Ashley Twichell, Jacob Pebley and Tom Shields to endorse Red Ace as the beverage of choice for the country's highest-level competitors.

"It is an honor to be chosen by the highest-performing athletes in the world as their beverage of choice for increased performance," Red Ace co-founder and President William Leslie IV said. "Ashley, Jacob and Tom are very discerning as to what they put in their bodies, and the brand they trust is Red Ace. We know that is a great privilege."

Founded in 2011 by William Leslie and Miles McCabe, Red Ace Organics offers a range of organic beverages and powders spanning the lifestyle segment, with its proprietary formulations of Beet Performance, Beets & Turmeric and Beets & Greens. Red Ace boasts more than 1,400 points of distribution, including Whole Foods Markets (WFM), Sprouts Farmers Markets and Amazon.

"I only associate myself with products I believe in," said Tom Shields, who won gold in Rio de Janeiro as part of the 4x100 medley relay. "Red Ace Beet Performance is something I would buy, even if Red Ace weren't my sponsor."

Red Ace products are packed with antioxidants as well as naturally occurring nitrates, which are compounds that help improve blood flow within the body to the brain, heart and muscles. Recent studies have indicated that many exercise scenarios and athletic competitions can have their performance capacity enhanced with the use of beet root juice as a pre-exercise supplement. Swimmers rely heavily on their bodies' ability to transfer vital oxygen to muscles during heavy training sessions and high stakes races.

"The first time I was introduced to Red Ace, I gave it a shot, and loved it," Ashley Twichell, who won the gold medal in the 5K at the 2017 FINA World Championships, said. "Beets and Turmeric is my favorite -- I drink it every day."

The natural nitrates found in Red Ace products increase nitric oxide in the blood, allowing for the vessels to open up and more oxygen to pass through, potentially lowering blood pressure. A healthy athlete is a successful athlete, and any consumer looking to improve their health in this area is well-served - as Olympic swimmers can attest.

"Our nutritionist told me to try Red Ace Beet Performance, and I immediately saw a difference in my recovery and overall performance. I recommend taking Red Ace daily," four-time World Championship medalist Jacob Pebley said.

The Alkaline Water Company Inc. (NASDAQ:WTER) (TSXV: WTER), a producer of premium bottled alkaline and flavored water sold under the brand names Alkaline88® and A88, respectively, announced its partnership with Youtech & Associates to develop and launch A88CBD.com, an end-to-end E-Commerce website that will immediately offer the Company's suite of CBD infused topical products for sale to consumers. The expected launch date of the E-Commerce website will be February 20, 2020.

According to Grand View Research, Inc., the global CBD skincare market is valued at $234.1 million and expected to expand at a CAGR of 32.9% from 2019 to 2025, thereby reaching a value of $1.7 billion.

"With a trusted brand as strong as Alkaline88®, we have positioned our A88CBD brand to be a significant and strong emerging brand in two of the highest growth and in-demand verticals of the CBD space. The E-Commerce platform marks our aggressive launch into topicals as a result of our existing loyal customers' and retail partners' interest in our trusted brand. In the coming weeks, I would expect news and a direction with timelines for our highly anticipated and in-demand ingestibles product portfolio," stated Richard A. Wright, President, and CEO of The Alkaline Water Company.

"The rollout of our E-Commerce strategy complements our brick-and-mortar approach as it will make our products accessible to our customers today, no matter where they reside. Our new E-Commerce platform will be fully optimized for mobile, ensuring that our customers have a simple and seamless shopping experience across all touchpoints."

To develop and launch A88CBD.com, the Company has partnered with industry-leading integrated marketing and development agency, Youtech. Under the agreement, Youtech will develop a unique E-Commerce strategy for A88CBD.com to support its launch through SEO optimization, social media promotions, and influencer marketing. This agreement will allow the Company to take full advantage of the tremendous opportunity E-Commerce presents for its growing line of CBD infused products.

Wilbur You, Founder and CEO of Youtech, further added, "This partnership is a no-brainer. We selected A88CBD as a brand to work with because we believe that in the long term it will be a trusted, well-known brand that will ultimately deliver the best products to the CBD community. We see the Cannabis industry evolving before us, and Alkaline88® as a brand is focused on better people, better quality and better results. In an industry currently devoid of top-quality options, we're excited to have the opportunity to bring the same quality to consumers on a mass scale. More importantly, everyone understands their role and value in making both Alkaline88® and Youtech better. I'm extremely humbled to have an opportunity to help lead Alkaline into the CBD market."

The CBD market is expected to grow to over $20 billion by 2024, according to BDS Analytics. BDS Analytics' estimates indicate that the $4.1 billion CBD derivatives market is currently served primarily through dispensaries, with the E-Commerce representing roughly $575 million or 14% of the current market. The industry research firm anticipates the E-Commerce segment to grow to $3.6 billion by 2024.

Also today, the Company announced that it has terminated its proposed acquisition of AQUAhydrate, Inc. Under the terms of the previously announced acquisition, either party had the right to terminate the agreement if the acquisition was not consummated on or before January 31, 2020.

"The termination of the transaction with AQUAhydrate allows us to focus all of our attention and resources on the core strategy of growing our flagship Alkaline88 brand and our A88CBD brand. We view the launch of our portfolio of CBD infused topical products as a massive opportunity for the Company, and we can now fully focus on pursuing the growth of Alkaline88®, A88 Infused Flavors, and A88CBD," remarked Richard Wright, the Company's President and CEO.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the

Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/investorideas_potcast/

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800-665-0411




Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.